Personalis (NASDAQ:PSNL) was the recipient of a significant growth in short interest in the month of November. As of November 29th, there was short interest totalling 886,700 shares, a growth of 14.8% from the November 14th total of 772,400 shares. Approximately 5.5% of the shares of the stock are sold short. Based on an average daily volume of 295,900 shares, the short-interest ratio is presently 3.0 days.
NASDAQ:PSNL traded up $0.51 during mid-day trading on Friday, hitting $10.21. 370,619 shares of the company’s stock traded hands, compared to its average volume of 319,255. The business has a 50 day simple moving average of $9.82. Personalis has a 1 year low of $8.48 and a 1 year high of $31.88.
Personalis (NASDAQ:PSNL) last posted its earnings results on Wednesday, November 13th. The company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03. The business had revenue of $17.20 million for the quarter, compared to analysts’ expectations of $15.77 million. The business’s quarterly revenue was up 47.0% on a year-over-year basis. As a group, sell-side analysts predict that Personalis will post -0.9 EPS for the current year.
Several analysts recently commented on PSNL shares. Bank of America upgraded shares of Personalis from a “neutral” rating to a “buy” rating and set a $22.00 price objective for the company in a research note on Thursday, September 26th. Zacks Investment Research cut shares of Personalis from a “buy” rating to a “hold” rating in a research note on Tuesday, November 19th. Finally, Oppenheimer reduced their price objective on shares of Personalis from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $23.60.
A number of large investors have recently bought and sold shares of PSNL. Board of Trustees of The Leland Stanford Junior University purchased a new position in Personalis during the 2nd quarter valued at about $38,749,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new position in Personalis during the 3rd quarter valued at about $11,775,000. Nikko Asset Management Americas Inc. purchased a new position in Personalis during the 3rd quarter valued at about $11,775,000. JPMorgan Chase & Co. purchased a new position in Personalis during the 2nd quarter valued at about $17,685,000. Finally, Janus Henderson Group PLC purchased a new position in Personalis during the 2nd quarter valued at about $13,554,000. Hedge funds and other institutional investors own 50.46% of the company’s stock.
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Recommended Story: Benefits of owning preferred stock
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.